Merck & Co. Inc / Genentech / Agency for Healthcare Research / Vertex / /
Continent
Asia / /
Country
United States / /
Event
FDA Phase / Bankruptcy / /
IndustryTerm
treatment of HCV / HCV therapies / technology assessments / HCV treatment / Treatment for Hepatitis C / healthcare providers / Hepatitis C treatment / /
MedicalCondition
references Hepatitis C / HIV / liver failure / cirrhosis / hepatocellular cancer / endstage renal disease / hepatitis C / rash overall / severe rash / end-stage renal disease / chronic HCV infection / liver disease / treatment-naive chronic hepatitis C. Specifically / cancer / disease / hepatocellular carcinoma / chronic HCV / HCV / HCV infection / Virus Infection / liver cancer / infection / renal failure / rash / baseline fibrosis / HCV RNA / /
MedicalTreatment
antiviral therapy / antiviral therapies / /
Organization
Telaprevir’s association / U.S. Preventive Services Task Force / FDA / Oregon Evidence-based Practice Center / Technical Expert Panel / FDA AHRQ / Agency for Healthcare Research and Quality / /
Person
Sammy Saab Peer Reviewer / Andrew H. Talal / Kenneth E. Sherman / Richard Chapell / Eugene R. Schiff / Eric Chak / /
Position
commentator / General / Executive / General National Viral Hepatitis Roundtable / representative / /
Disposition of Comments Report for Treatment for Hepatitis C Virus Infection in Adults